Abstract-The effects of Simvastatin (MK-733), an inhibitor of 3-hydroxy-3 methylglutaryl CoA (HMG-CoA) reductase, on fecal and biliary excretion of sterols and bile acids were examined using rabbits.
2-9-3, Shimomeguro, Meguro-ku, Tokyo 153, Japan Accepted January 12, 1990 Abstract-The effects of Simvastatin , an inhibitor of 3-hydroxy-3 methylglutaryl CoA (HMG-CoA) reductase, on fecal and biliary excretion of sterols and bile acids were examined using rabbits.
Multiple doses of MK-733 (10 mg/ kg/day) for 7 days were found to increase fecal concentrations of neutral sterols in cholesterol-fed rabbits, but not to affect those of bile acids. Multiple doses of cholestyramine (750 mg/kg/day), a bile acid sequestrant, for 7 days increased fecal concentrations of neutral sterols and bile acids in normally fed and cholesterol-fed groups.
MK-733 did not affect biliary neutral sterols and total bile acids in normally fed and cholesterol-fed groups. Cholestyramine decreased biliary concentrations of neutral sterols in both diet groups.
Cholestyramine altered fecal and biliary composition of bile acids, but MK-733 did not. It was considered that MK-733 inhibited the absorption of cholesterol, resulting in an increase of the fecal concen tration of neutral sterols in cholesterol-fed rabbits. The mechanism of action of MK-733 in the inhibition of cholesterol absorption is considered to be clearly differ ent from that of cholestyramine.
These results confirmed the conclusion in the previous experiment.
Simvastatin (1) is a chemical derivative of lovastatin which is a potent competitive inhibitor of 3-hydroxy 3-methylglutaryl CoA reductase (HMG-CoA reductase) (2).
In our previous experiment, it was demon strated that MK-733 inhibited the develop ment of hypercholesterolemia and athero sclerosis in cholesterol-fed rabbits (3). We have already reported that this hypolipidemic effect was related to a marked inhibition of the absorption of exogenous cholesterol from the gastrointestinal wall (4). There are, theoretically, three mechanisms to control the serum cholesterol pool: 1) de creased absorption of dietary cholesterol, 2) decreased synthesis of cholesterol and 3) in creased excretion of either or both cholesterol and its metabolites, the bile acids (5). From the results in our previous study of [3H] cholesterol absorption and excretion in cho lesterol-fed rabbits (4), an increase in the fecal excretion of neutral sterols in rabbits treated with MK-733 would be expected. However, we have not yet examined the effect of MK-733 on sterol balance in rabbits. Bile acid excretion is thought to be a principal route of cholesterol removal and the remainder of the cholesterol is eliminated from the body in the form of biliary cholesterol (6, 7). In the present study, therefore, we examined the effect of MK-733 on biliary and fecal excre tion of neutral sterols and bile acids. Cho lestyramine, a bile acid sequestrant, has been reported to disrupt the entero-hepatic circula tion of bile acids, resulting in the inhibition of cholesterol absorption in several experimental animals (8-11).
Therefore, cholestyramine was used as a reference drug. 2. Animals: Male Japanese white rabbits aged 16 to 23 weeks and weighing 2.5 to 3.1 kg were used in this study. These animals were purchased from Clean Experimental Animals Co., Ltd. (Saitama, Japan) and main tained under the following environmental conditions: room temperature, 23±2'C, rela tive humidity, 55±15%; illumination, 12 hr from 6 A.M. to 6 P.M. The rabbits were housed in metal cages individually and were given a normal chow pellet (RC-4, Oriental Yeast, Tokyo, Japan) and water ad libitum for at least 4 weeks in order to acclimatize the animals.
Rabbits were divided into approximately equal weight groups and housed in metabolic cages individually. One hundred grams of the normal diet was given to each animal per 3 kg of body weight in Groups A, B and C through out the study except for an overnight fasting before the bile duct cannulation, and water was given ad libitum. Animals in Group D were given a diet containing 2.25% cholestyr amine. The dosage of cholestyramine was about 750 mg/kg/day. Rabbits in Groups E, F and G were fed a diet containing 1 % cho lesterol for 7 days and were fasted in a similar manner in Groups A, B and C. Animals in Group H were given a diet containing both 1 % cholesterol and 2.25% cholestyramine. MK 733 was suspended with 0.5% carboxyme thylcellulose sodium salt, using an ultrasonic homogenizer, and it was administered orally by a stomach catheter. In the multiple ad ministration experiment, MK-733 at a dose of 10 mg/kg/day was administered orally once a day for 8 days to Groups C and G. In the single dosing experiment to define the acute effect of MK-733 on biliary lipids excretion, MK-733 was administered once on the 8th day to Groups B and F. In Groups D and H, animals were given a dose of 750 mg/kg of cholestyramine suspended in water on the 8th day. Rabbits in the control groups (Groups A and E) were given 0.5% CIVIC solution alone orally for 8 days. On the 8th day, the drug or vehicle was administered orally just before the bile duct cannulation in all groups. After that, rabbits were anesthetized with halothane following the administration of thiopental sodium (20 mg/kg, i.v.) and atropine (0.1 mg/ rabbit, i.v.), and the common bile duct was cannulated with SP-45 polyethylene tubing (Natsume, Tokyo, Japan) to collect bile for 2 hr. For the sterol balance study, feces and urine were collected for three days before the operation in the multiple-dose experiment (Groups A, C, D, E, G and H).
3. Determination of serum lipid levels: Serum lipid levels were determined on the 8th day. Total cholesterol, free cholesterol and phospholipids
were measured with an auto analyzer (Centrifichem, Encore, Baker Instru ment Co., Allenton, PA, U.S.A.), using Deter miner TC555 (Kyowa Medex, Tokyo, Japan) Determiner FC555 (Kyowa Medex) and Determiner PL (Kyowa Medex), respectively. Serum total bile acids were determined by an enzymatic method using Total Bile Acids Test Wako (Wako Pure Chemical Co.).
4. Measurement of lipid content in the liver: Lipids in the liver were extracted ac cording to Folch et al. (12) . The solvent was evaporated under a stream of nitrogen, and the lipid extract was redissolved with an aliquot of isopropyl alcohol. Total and free cholesterol concentrations were determined as described in the section on determination of serum lipid levels. Phospholipid concen trations were determined using a chemical assay kit (Phospholipid-Test Wako, Wako Pure Chemical Co.).
5. Biliary lipid determination: Bile was col lected from the cannulated common bile for 2 hr. Biliary bile acids and neutral sterols were determined according to the method of Imai et al. (13) with some modifications. The bile was extracted with ethanol after the addition of internal standards (5a-cholestane 10 ug/ ml bile and 5a-cholanic acid 1 mg/ml bile); one volume of the bile was mixed with 20 volumes of ethanol, boiled for about 5 min and filtered after cooling down to room tempera ture. Whole filtrate was evaporated to dryness under a stream of nitrogen, and the residue was hydrolyzed in 2 ml of 1.25 M NaOH for 6 hr at 120°C in an autoclave. Neutral sterols were extracted with diethyl ether; bile acids were then extracted with diethyl ether after acidification with 2 M HCI. Neutral sterols were determined by gas liquid chromato graphy (GLC) on an HP-1 fused silica megabore column (10 mx0.53 mm, 2.65 im film thickness, Hewlett Packard, CA, U.S.A.). All GLC analyses were performed on an instrument (GC-9A, Shimadzu, Kyoto, Japan) equipped with a hydrogen flame ionization detector. Bile acids were converted to methyl ester derivatives using trimethylsilyldiazo methane (Tokyo Chemical Industry Co., Ltd., Tokyo, Japan) and determined by GLC using an HP-1. Phospholipids were determined by a chemical method using the assay kit as described above. The lithogenic index was calculated from the following formula: neutral sterols (mol)/(phospholipids (mol)+total bile acids (mol)).
6. Fecal sterols and bile acids determina tion: Fecal neutral sterols and bile acids were determined according to the method of Huff and Carroll (14) with some modifications. Feces were collected for 3 days before the bile cannulation, lyophilized and ground. Four hundred micrograms of 5a-cholestane was added to 0.2 g of freeze-dried feces as an internal standard. The freeze-dried, ground feces (0.2 g) was saponified in 5 ml 1 M NaOH in 90% ethanol for 1.5 hr. The neutral sterols were extracted with 12.5 ml of petroleum ether three times after dilution with 2.5 ml of water and then backwashed with 15 ml of H20. Neutral sterols were determined by GLC on an HP-1 column. The overall recovery of bile acids was determined by the addition of [2,4-3H]cholic acid. One-half milliliter of 10 M NaOH was added to the lower aqueous phase, and then the solution was autoclaved for 3 hr at 120°C. The sample was acidified, and the bile acids were extracted with chloroform/methanol (2:1, v/v) once and chloroform twice. The bulk of the fatty acids was removed on a Florisil cartridge (Sep-Pack, Waters Associates, MA, U.S.A.). The bile acid fraction was methylated using trimethylsilyldiazomethane.
The methyl esters were extracted with diethyl ether after the addition of water. The efficiency of this methylation procedure was determined by the recovery of added [2,4-3H]cholic acid as its methyl ester and was found to be 98%. After adding 5a-cholestane as an internal standard, the bile acid methyl esters were exposed to silylating reagent (N-trimethylsilylimidazole, Pierce Chemical Co., IL, U.S.A.) in order to convert all free hydroxy groups to trimeth ylsilyl ethers. Silylation of standard samples was confirmed using GC-mass spectrometry. Bile acids were determined by GLC on an HP-1 column. The identity of the neutral sterols and bile acids was determined by com parison to authentic standards.
7. Data analysis: Data from these studies were statistically analyzed using Wilcoxon's rank-sum test (15). The variations in all mean values in the tables and figures are expressed as standard deviation (S.D.).
Results

General observations:
There was no remarkable difference in the body weight and food intake between the control and drug treated groups. No adverse effect in gross ob servations was seen in any rabbits in the entire group during the experiment. No visible gross change was observed in any organ or tissue at necropsy.
2. Serum lipid and total bile acid levels: As shown in Fig. 1 , multiple administration of MK-733 (10 mg/kg/day) and cholestyramine (750 mg/kg/day) decreased serum total cholesterol levels significantly in normally fed rabbits. Cholestyramine also decreased free cholesterol and phospholipid levels in the normally fed rabbits. Total cholesterol levels were increased to 613.6 mg/dl after the fe eding of a 1 % cholesterol diet for 7 days. Multiple-dose treatment with MK-733 limited the increase in serum cholesterol levels to 139.9 mg/dl. Cholestyramine inhibited the increase in the cholesterol levels to 46.7 mg/ dl. The serum phospholipid levels were also increased by cholesterol feeding for 7 days, and reached 190 mg/dl. MK-733 and cho lestyramine limited the increase in phospho lipid levels significantly. Serum triacylglycerol concentrations varied during the experi mental period in all animals (data not shown). Cholesterol feeding tended to increase serum total bile acid concentrations (Fig. 2) . Cho lestyramine decreased serum total bile acid levels in the normally fed and cholesterol-fed rabbits. On the other hand, MK-733 did not affect serum total bile acid levels in either diet group. Fig. 1 . Effects of MK-733 and cholestyramine on serum lipid levels. Rabbits in groups A (n=4), C (n=5) and D (n=4) were fed a normal diet. Rabbits in groups E (n=4), G (n=4) and H (n=4) received a 1 % cholesterol diet. MK-733 at a dose of 10 mg/ kg/day was administered orally once a day for 7 days in groups C and G. Rabbits in control groups A and E were orally given 0.5% CMC alone. Cholestyramine at a dose of 750 mg/kg/day was administered by incorporation (2.25%) into each diet to rabbits in groups D and H. Serum total cholesterol (TC), free cholesterol (FC) and phospholipids (PL) were determined on the 8th day as described in Materials and Methods. The values represent the mean and S.D. of each group, respectively. Significantly different from the value in each control group: *P<0 .05. Fig. 2 . Effects of MK-733 and cholestyramine on serum total bile acid levels. MK-733 at a dose of 10 mg/kg/day was administered orally once a day for 7 days in groups C (n=5) and G (n=4). Rabbits in control groups A (n=4) and E (n=4) were orally given 0.5% CIVIC alone. Cholestyramine at a dose of 750 mg/kg/day was administered by incorporation into each diet to rabbits in groups D (n=4) and H (n=4). Serum total bile acids were determined on the 8th day as described in Materials and Methods. The values represent the mean and S.D. of each group, respectively. Significantly different from the value in each control group: *P<0.05. the liver was present as free cholesterol in the normal diet groups. Cholestyramine de creased esterified cholesterol content. Cho lesterol feeding increased the free and ester ified cholesterol levels in the liver without af fecting the phospholipid content. Multiple dose treatment with MK-733 inhibited the ac cumulation of free and esterified cholesterol in the liver. Cholestyramine also inhibited the ac cumulation of free and esterified cholesterol in the liver. Neither MK-733 nor cholestyr amine altered the phospholipid levels. There were fluctuations in triac","glycerol levels in all animals (data not shown). (n=4) and F (n=4) and at multiple doses of 10 mg/ kg/day once a day for 8 days in groups C (n=5) and G (n=4). Rabbits in groups A (n=4) and E (n=4) received 0.5% CMC solution alone for 8 days.
Cholestyramine at a dose of 750 mg/kg/day was given by incorporation in each diet to rabbits in groups D (n=4) and H (n=4). On the 8th day, the drug or vehicle was administered orally just before the bile duct cannulation in all groups. The bile was collected from the common bile duct for 2 hr after bile duct cannulation as described in the text. The values represent the mean and S.D. of each group, respectively. Significantly different from the value in each control group: *P<0.05. pholipids and total bile acids. MK-733 was adminis tered orally at a single dose of 10 mg/kg/day on the 8th day in groups B (n=4) and F (n=4) and at multiple doses of 10 mg/kg/day once a day for 8 days in groups C (n=5) and G (n=4). Rabbits in groups A (n=4) and E (n=4) received 0.5% CMC solution alone for 8 days. Cholestyramine at a dose of 750 mg/kg/day was given by incorporation in each diet to rabbits in groups D (n=4) and H (n=4). On the 8th day, the drug or vehicle was adminis tered orally just before the bile duct cannulation in all groups. The bile was collected from the common bile duct for 2 hr after bile duct cannulation as described in the text. Biliary neutral sterols and bile acids were determined by GLC analysis as described in the text. rabbits. Almost all neutral sterol was excreted into the bile as cholesterol in each animal (data not shown). A small quantity of campesterol and Q-sitosterol was detected in the bile. These sterols were in cluded for calculation of the lithogenic index. Multiple-dose treatment with MK-733 did not affect the concentrations of phospholipids or total bile acids in the normally fed or choles terol-fed rabbits. Cholestyramine did not affect the concentrations of phospholipids or total bile acids in the normally fed rabbits, but it decreased phospholipids in the cholesterol fed rabbits. It did not affect the concentration of total bile acids in the cholesterol-fed rabbits. Multiple-dose treatment with MK-733 decreased the litho genic index in the normally fed rabbits, but did not affect it in the cholesterol-fed rabbits (Fig.  5) . Single-dose treatment with MK-733 did not affect the lithogenic index in normally fed or cholesterol-fed rabbits. Cholestyramine de creased the lithogenic index in normally fed and cholesterol-fed rabbits. 5. Fecal lipids: As shown in Fig. 6 , neither MK-733 nor cholestyramine affected the weight of feces in normally fed or cholesterol fed rabbits. Cholesterol feeding increased the concentration of total bile acids and neutral sterols in the feces significantly.
Multiple dose treatment with MK-733 increased the neutral sterol concentration in the cholesterol fed rabbits, but decreased it in the normally fed rabbits (only significant in the t-test). Cholestyramine increased the neutral sterol concentration in the normally fed or choles terol-fed rabbits. MK-733 did not affect the concentration of total bile acids in the normal ly fed or cholesterol-fed rabbits. Cholestyr amine increased the concentration of total bile acids in the normally fed and cholesterol fed-rabbits. The predominant bile acid in the feces was 12-keto-lithocholic acid in the normally fed and cholesterol-fed rabbits (60.7% and 55.4%, respectively) ( Table 3) . Deoxycholic acid and lithocholic acid were also detected in the feces in the normally fed and cholesterol-fed rabbits. MK-733 did not affect the bile acid composition in normally fed or cholesterol-fed rabbits. Cholestyramine decreased the ratio of 1 2-keto-lithocholic acid and increased the ratio of deoxycholic acid in the cholesterol-fed rabbits. It also increased the ratio of deoxycholic acid and tended to decrease the ratio of 12-keto lithocholic acid in normally fed rabbits. Cholesterol and coprostanol were major neutral sterols in the feces in the normally fed and cholesterol-fed rabbits, but there was a great variance in the composition of neutral sterols. Therefore, a significant difference was not detected in neutral sterol composition in either group.
Cholesterol absorption was calculated from the difference between the amount of dietary cholesterol administered and the amount of fecal neutral sterols excreted. Cholesterol absorption was 47.2% in the control cholesterol-fed rabbits. MK 733 and cholestyramine decreased the absorption of cholesterol to 29.7 and 26.2%, respectively, but not significantly (data not shown). Fig. 6 . Effects of MK-733 and cholestyramine on fecal weight, neutral sterols and total bile acids in feces. MK-733 was administered orally at multiple doses of 10 mg/kg/day once a day for 8 days in groups C (n=5) and G (n=4). Rabbits in groups A (n=4) and E (n=4) received 0.5% CIVIC solution alone for 8 days. Cholestyramine at a dose of 750 mg/kg/day was given by incorporation in each diet to rabbits in groups D (n=4) and H (n=4). Feces were collected for 3 days before bile duct cannulation. Neutral sterols and bile acids in the feces were determined by GLC analysis as described in the text. The values represent the mean and S.D. of each group, respectively. Significantly different from the value in each control group: *P<0.05.
The excretion of urinary neutral sterols and bile acids was less than 11% and 10% of fecal excretion, respectively (data not shown).
Discussion
In the present experiment, MK-733 was found to increase the fecal neutral sterol con centrations, but not to affect the fecal bile acid concentrations in the cholesterol-fed rabbits. MK-733 did not increase the biliary concen tration of neutral sterols, total bile acids or phospholipids, and it did not change the com position of biliary neutral sterols and bile acids in the cholesterol-fed rabbits. We have already demonstrated that MK-733 inhibited [3H] cholesterol absorption in cholesterol-fed rab bits (4). Theatment with M K-733 (10 mg/kg) clearly reduced the serum [3H]-radioactivity in the cholesterol-fed rabbits. The area under the serum radioactive concentration-time curve (AUC) calculated from the serum radioactivity in the MK-733 group was about 9.6% of that in the control group. The cumula tive excretion of the fecal radioactivity of [3H]cholesterol in the MK-733 group was higher than that in the control group. The results in the present study agree well with those in the previous one. Cholestyramine, a bile acid sequestrant, increased fecal concen trations of total bile acids and neutral sterols in the cholesterol-fed rabbits. Cholestyramine decreased the bile flow, the biliary concen trations of neutral sterols and phospholipids. Therefore, the inhibitory mechanism of MK 733 on the absorption of cholesterol was con sidered to be different from that of cholestyr amine. Intestinal acyl coenzyme A:cholesterol acyltransferase (ACAT) activity is thought to participate in the cholesterol absorption. Heider et al. reported that an ACAT inhibitor, 57-118, inhibited cholesterol absorption in cholesterol-fed rabbits, and they concluded that intestinal-mucosal ACAT plays a signifi cant role in cholesterol absorption (16). Re cently, MK-733 was found to cause a 70% reduction in microsomal ACAT activity of the intestinal mucosa relative to that observed in concurrent control rabbits (17). MK-733 is thought to inhibit the absorption of choles terol, because it decreases microsomal ACAT activity in the intestinal mucosa. De novo cholesterol synthesis may be related to the regulation of microsomal ACAT activity. Khan et al. reported that lovastatin (MK-803) may act by mechanisms other than as an inhibitor of cholesterol synthesis to decrease the hepatic pool of cholesterol ester in rats (18). Furthermore, they speculate that newly synthesized cholesterol may be essential to the formation and secretion of very low density lipoprotein (VLDL). MK-733 may suppress the formation and secretion of VLDL and/or chylomicron in the intestinal mucosa by inhibiting de novo cholesterol synthesis. MK-733 is considered to inhibit cholesterol absorption in cholesterol-fed rabbits, resulting in an increase in neutral sterol excretion in the feces. On the other hand, cholestyramine interrupts the entero-hepatic circulation of bile acids and inhibits the absorption of neutral sterols (8-11). Both drugs increased the fecal excretion of neutral sterols, but the mechanism of action of MK-733 and choles tyramine is thought to be clearly different.
MK-733 tended to decrease neutral sterol concentration in the feces in normally fed rabbits. It did not increase the biliary excre tion of neutral sterols, total bile acids or phos pholipids, and it did not change the composi tion of neutral sterols and bile acids in normal ly fed rabbits. Almost all cholesterol excreted in the feces is considered to be derived from endogenously synthesized cholesterol in the normally fed rabbits. Therefore, MK-733 is considered to inhibit de novo cholesterol synthesis in normally fed rabbits, resulting in a decrease in fecal neutral sterol concentrations. Cholestyramine increased the fecal concen tration of bile acids in the normally fed rabbits. Cholestyramine decreased the secondary bile acid, 1 2-keto-lithocholic acid and increased deoxycholic acid in the feces. Huff and Carroll (14) reported that deoxycholic acid, litho cholic acid and 12-keto-lithocholic acid were the major bile acids detected in rabbit feces. These were present in approximately equal proportions in rabbits fed a casein or soy protein diet. They also reported that choles terol and coprostanol were the major neutral sterols in rabbit feces. We also detected these bile acids and neutral sterols in rabbit feces. However, the ratio of fecal bile acids in our experiment was different from that in the ex periment of Huff and Carroll (commercial diet) (14). This may have been caused by the difference in the composition of the diets used in our experiment and their experiment. The primary bile acid, cholic acid, is converted to the secondary bile acid, deoxycholic acid (19) and then converted to 12-keto-lithocholic acid by intestinal bacteria (20). Cholestyr amine is considered to prevent the resorption of bile acids, resulting in an increase in bile acid excretion (8) (9) (10) (11) . Therefore, the re sidence time of bile acids in the body via the entero-hepatic circulation is considered to be less in cholestyramine treated rabbits than in control rabbits. So, the ratio of deoxycholic acid/1 2-keto-lithocholic acid is considered to be increased in feces. Cholestyramine de creased the concentration of biliary bile acids, because it inhibits the entro-hepatic circula tion of bile acids. This phenomenon is also proved by the decreased levels of bile acids in the serum in the cholestyramine-treated rab bits. MK-733 did not show any effect on biliary bile acids or neutral sterols.
Hellstrom (21) reported that cholesterol feeding reduced fecal excretion of deoxy cholic acid and did not influence the bile acid absorption in rabbits. In our experiment, biliary and fecal excretion of deoxycholic acid was slightly decreased by cholesterol feeding.
In bile, cholesterol is solubilized as mixed micelles of bile acids, phospholipids, etc., and the solubility of cholesterol in the bile depends on the relative proportions of these constituents (22) (23) (24) . Therefore, we ex amined the lithogenic index in bile. Multiple dose treatment with MK-733 decreased the lithogenic index in the normally fed rabbits, but did not affect it in the cholesterol-fed rabbits. MK-733 is not considered to affect bile acid excretion directly, because a single dose of MK-733 did not affect the biliary neutral sterol or bile acid concentrations. It has been reported that treatment with pravas tatin sodium (CS-514) (25-27), another HMG-CoA reductase inhibitor, at doses of 50 mg/kg for 5 weeks lowered the lithogenic index of bile in dogs (28) and that MK-733 also reduced the lithogenic index of cholecys tic bile in humans (29). These findings sug gest that treatment with HMG-CoA reductase inhibitors will not predispose an individual to development of cholesterol gallstones.
From these results, it was considered that MK-733 inhibited the absorption of choles terol, resulting in an increase of the fecal con centration of neutral sterols in cholesterol-fed rabbits. The present results in terms of the sterol balance confirm the conclusion that M K-733 inhibits the absorption of cholesterol, resulting in a suppression of hypercholestero lemia in cholesterol-fed rabbits in our previous experiment (4).
